目的：探讨噻托溴铵联合沙美特罗/丙酸氟替卡松吸入治疗对慢性阻塞性肺疾病(COPD)患者肺功能的影响情况。方法分析抚顺市中心医院2013年1月~2015年1月收治的75例COPD患者临床资料,依据治疗措施不同进行分组,普通治疗组(解痉平喘基础治疗)35例和联合治疗组(噻托溴铵联合沙美特罗/丙酸氟替卡松吸入治疗)40例。观察两组患者治疗前后临床症状评分、肺功能、临床治疗总有效率情况。肺功能采用肺功能仪进行检测。结果两组COPD患者治疗前临床症状评分[(6.60±2.21)比(7.14±2.32)分]比较差异无统计学意义(t=1.03, P>0.05),联合治疗组慢性阻塞性肺疾病患者治疗后临床症状评分[(4.23±1.62)分]均优于普通治疗组[(5.66±1.45)分],差异均有统计学意义(t=4.00,P<0.05)。两组COPD患者治疗前FEV1[(1.12±0.67)比(1.13±0.58)L]、FEV1/FVC%[(52.28±3.29)%比(52.48±3.64)%]、FEV1%Pred[(52.34±4.03)%比(53.16±3.92)%]差异无统计学意义(t=0.07、0.25、0.89,P>0.05),联合治疗组COPD患者治疗后FEV1[(1.96±0.55)L]、FEV1/FVC%[(59.92±3.47)%]、FEV1%Pred[(63.12±5.24)%]均优于普通治疗组[(1.54±0.48)L、(56.20±3.24)%、(56.72±4.87)%],差异均有统计学意义(t=3.50、4.78、5.45,P<0.05)。联合治疗组COPD患者临床治疗总有效率(100.0%)高于普通治疗组(74.3%),差异均有统计学意义(χ2=29.49,P<0.05)。结论噻托溴铵联合沙美特罗/丙酸氟替卡松吸入治疗COPD患者临床效果明显,预后良好,值得临床推广应用。%Objective To explore effect of Tiotropium Bromide combined with Salmeterol/Fluticasone Propionate treat-ment on lung function of COPD patients. Methods clinical data of 75 cases of COPD patients in the Central Hospital of Fushun City from January 2013 to January 2015 were analyzed, According to different treatment method, they were di-vided into two groups, general treatment group (Spasmolysis and asthma foundation treatment) 35 cases and combined treatment group (Tiotropium Bromide unite Salmeterol/Fluticasone Propionate treatment) 40 cases. The clinical symptom scores, lung function, total effective rate of clinical treatment of two groups of patients before treatment and after treat-ment were detected. The lung function was tested by lung function instrument. Results There was no statiscal difference of clinical symptom scores [(6.60±2.21) vs (7.14±2.32) scores] between two groups of COPD patients before treatment (t=1.03, P> 0.05). There was no statiscal difference of FEV1 [(1.12±0.67) vs (1.13±0.58) L], FEV1/FVC% [(52.28± 3.29)%v s (52.48±3.64)%L], FEV1%Pred [(52.34±4.03)%v s (53.16±3.92)%] between two groups of COPD patients be-fore treatment (t=0.07, 0.25, 0.89, P> 0.05). The clinical symptom score [(4.23 ±1.62)scores] of combined treatment group COPD patients after treatment was better than general treatment group [(5.66±1.45)scores, t=4.00, P<0.05]. The FEV1 [(1.96±0.55)L], FEV1/FVC% [(59.92±3.47)%], FEV1%Pred [(63.12±5.24)%] of combined treatment group after treatment were better than general treatment group [(1.54±0.48)L, (56.20±3.24)%, (56.72±4.87)%] (t=3.50, 4.78, 5.45, P < 0.05), the clinical effective rate (100.0%) of combined treatment group COPD patients was higher than general treatment group (74.3%), the difference were statistically significant (χ2=29.49, P<0.05). Conclusion The clinical effa-cy of tiotropium bromide combined with salmeterol/ fluticasone propionate treatment on COPD patients is obvious, has good prognosis, which is worthy of clinical application.
展开▼
